Iterum Therapeutics Plc's Comment on Sales, Marketing and Customers
Pharmaceutical manufacturers operate within a regulatory framework that includes compliance with healthcare laws such as the federal Anti-Kickback Statute, the federal False Claims Act, the Health Insurance Portability and Accountability Act (HIPAA), the Physician Payments Sunshine Act, and corresponding state and foreign regulations. These laws affect the marketing, sale, and distribution of drug products and are subject to increasing enforcement by federal and state authorities. Additionally, healthcare reform initiatives in the United States, including the Affordable Care Act (ACA) and the Budget Control Act of 2011, influence coverage and payment policies for drug products under government healthcare programs, with the objective of reducing healthcare costs.
DUBLIN and CHICAGO, Aug. 02, 2024 Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company dedicated to the advancement of innovative oral and intravenous antibiotics, has announced significant progress in its intellectual property portfolio. The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for two new U.S. patents, while the Canadian Intellectual Property Office (CIPO) has granted a Canadian patent, all pertaining to the company s novel formulation of sulopenem etzadroxil in combination with probenecid, referred to as oral sulopenem.These new patents are crucial for Iterum as they bolster its competitive position in the battle against antibioti...
Iterum Therapeutics plc, a leading clinical-stage pharmaceutical company specializing in the development of advanced oral and intravenous antibiotics to combat infections caused by multi-drug resistant pathogens, announced its participation in the prestigious American Society for Microbiology (ASM) Microbe 2024 meeting. The event, scheduled from June 13th to 17th in Atlanta, Georgia, will serve as a platform for sharing cutting-edge research and fostering collaboration among top scientists and industry experts in the field.The Company s presence at the ASM Microbe 2024 meeting highlights its commitment to tackling the rising global threat of antibiotic resistance. With the emergence of multi-drug resistant p...
Iterum Therapeutics Plc’s Comment on Sales, Marketing and Customers
Pharmaceutical manufacturers operate within a regulatory framework that includes compliance with healthcare laws such as the federal Anti-Kickback Statute, the federal False Claims Act, the Health Insurance Portability and Accountability Act (HIPAA), the Physician Payments Sunshine Act, and corresponding state and foreign regulations. These laws affect the marketing, sale, and distribution of drug products and are subject to increasing enforcement by federal and state authorities. Additionally, healthcare reform initiatives in the United States, including the Affordable Care Act (ACA) and the Budget Control Act of 2011, influence coverage and payment policies for drug products under government healthcare programs, with the objective of reducing healthcare costs.
Sources:
Iterum Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Iterum Therapeutics Plc’s corporate clients.
For your research, we’ve provided 9 tables on Iterum Therapeutics Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
